Short answer
OPKO HEALTH, INC. (OPK) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers OPKO’s Q3 2026 operating and financial results for the quarter ended September 30, 2026.
OPKO HEALTH, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers OPKO’s Q3 2026 operating and financial results for the quarter ended September 30, 2026
- Conference call scheduled for business updates, financial results discussion and financial guidance
- Detailed highlights and guidance available in Exhibit 99.1, relevant for assessing outlook and operating momentum
Item EX-99.1 · Exhibit EX-99.1
- Q3 continuing-operations revenue $65.4M, up 16%, while net loss widened to $35.5M, or $0.05 per share
- Labcorp deal offers $722M upfront plus up to $150M tied to 4Kscore sales, pending approvals and closing conditions
- BioReference classified as discontinued operations, producing $18.0M Q3 loss versus $54.6M income in 2025
- Royalty financing added $125M, lifting senior secured royalty financing to $370.2M at September 30
- Cash and restricted cash $403.2M, with $84.3M remaining under the $200M share-repurchase authorization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OPKO HEALTH, INC. 8-K filings
Get the next OPK 8-K as it lands
Follow OPK for push alerts, or ask the research agent what this filing means.